Abstract 16351: Arrhythmic Events in Brugada Syndrome: A Nation-Wide Israeli Survey of the Clinical Characteristics, Treatment and Long-Term Follow-Up (ISRABRU-VF)

BackgroundSince the first report on Brugada syndrome (BrS), only sparse information has been reported on the detailed characteristics and management of the small subset of patients who had an arrhythmic event (AE). We conducted the first nationwide comprehensive survey focused on the detailed clinical, diagnostic work up, electrophysiological (EP) characteristics and long term management of BrS patients who have had an AE.MethodsAll 21 Israeli EP units were invited to participate in the survey if they have treated patients with BrS who had suffered a cardiac arrest (CA) (lethal or aborted)(group 1) or experienced appropriate therapy for VF/VT events after prophylactic ICD implantation (group 2). Analysis included all eligible BrS patients.ResultsA total of 31 patients met the inclusion criteria from the entire country25 in group 1 and 6 in group 2. In group 1, 96% of patients were male; mean age at CA was 38 years (range 13-84). Nine (36%) patients presented with arrhythmic storm and 3 (12%) had a lethal outcome. A spontaneous type1 Brugada-ECG was observed in 17 (68%) of patients. EPS was performed in 11 (44%) patients with inducible VF in 10, that was prevented by quinidine in 7/8 patients reexamined on treatment. During follow up (143±119 months) 8 (32%) patients (who were not taking quinidine) experienced at least 1 appropriate shock and 5 patients received an inappropriate shock. At last follow-up visit, 18 (72%) patients had an active ICD while 11 (44%) were receiving quinidine (9 concomitant with ICD). Group 2 patients were all male, age 30-53 (mean 42), 4/6 patients had a family history of sudden death age